Allogeneic bone marrow transplantation for AL amyloidosis

被引：26

作者：

Guillaume, B

Straetmans, N

Jadoul, M

Cosyns, JP

Ferrant, A

机构：

[1] UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,DEPT HEMATOL,B-1200 BRUSSELS,BELGIUM

[2] UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,DEPT NEPHROL,B-1200 BRUSSELS,BELGIUM

[3] UNIV CATHOLIQUE LOUVAIN,CLIN UNIV ST LUC,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM

来源：

BONE MARROW TRANSPLANTATION | 1997年 / 20卷 / 10期

关键词：

amyloidosis; allogeneic BMT;

D O I：

10.1038/sj.bmt.1700983

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

AL amyloidosis is an infiltrative disorder characterized by the extracellular deposition of insoluble fibrillar immunoglobulin light chains whose production results from a plasma cell dyscrasia. Treatment with melphalan has resulted in an improvement in a few patients. Recently, intensive chemotherapy followed by autologous or syngeneic stem cell support has been shown to offer potential benefit. Allogeneic stem cell support after intensive therapy would retain the benefits of autologous transplantation, with the additional advantages of a tumor-free graft and of a possible graft-versus-tumor effect. We report a patient with AL amyloidosis and significant proteinuria, She improved after an allogeneic bone marrow transplantation.

引用

页码：907 / 908

页数：2

共 11 条

[1] Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: A retrospective case-matched study from the European group for blood and marrow transplantation [J].

Bjorkstrand, B ;

Ljungman, P ;

Svensson, H ;

Hermans, J ;

Alegre, A ;

Apperley, J ;

Blade, J ;

Carlson, K ;

Cavo, M ;

Ferrant, A ;

Goldstone, AH ;

deLaurenzi, A ;

Majolino, I ;

Marcus, R ;

Prentice, HG ;

Remes, K ;

Samson, D ;

Sureda, A ;

Verdonck, LF ;

Volin, L ;

Gahrton, G .

BLOOD, 1996, 88 (12) :4711-4718

[2] Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients [J].

Comenzo, RL ;

Vosburgh, E ;

Simms, RW ;

Bergethon, P ;

Sarnacki, D ;

Finn, K ;

Dubrey, S ;

Faller, DV ;

Wright, DG ;

Falk, RH ;

Skinner, M .

BLOOD, 1996, 88 (07) :2801-2806

[3]

GERTZ MA, 1991, BLOOD, V77, P257

[4] A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine [J].

Kyle, RA ;

Gertz, MA ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Lacy, MQ ;

Therneau, TM .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (17) :1202-1207

[5]

KYLE RA, 1978, BLOOD, V52, P818

[6] PRIMARY SYSTEMIC AMYLOIDOSIS - RESOLUTION OF THE NEPHROTIC SYNDROME WITH MELPHALAN AND PREDNISONE [J].

KYLE, RA ;

WAGONER, RD ;

HOLLEY, KE .

ARCHIVES OF INTERNAL MEDICINE, 1982, 142 (08) :1445-1447

[7]

MAJOLINO I, 1993, HAEMATOLOGICA, V78, P68

[8]

MEHTA J, 1992, NEW ENGL J MED, V326, P1087

[9] Graft-versus-myeloma effect: Proof of principle [J].

Tricot, G ;

Vesole, DH ;

Jagannath, S ;

Hilton, J ;

Munshi, N ;

Barlogie, B .

BLOOD, 1996, 87 (03) :1196-1198

[10] CLINICAL REMISSION AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION IN A PATIENT WITH AL AMYLOIDOSIS [J].

VANBUREN, M ;

HENE, RJ ;

VERDONCK, LF ;

VERZIJLBERGEN, FJ ;

LOKHORST, HM .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (07) :508-510

← 1 2 →